Clinical Value of the MRI Combined With SCC-Ag for the Diagnosis of HSIL (CIN 2/3)

Sponsor
Second Affiliated Hospital of Wenzhou Medical University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05487209
Collaborator
(none)
186
1
22
8.4

Study Details

Study Description

Brief Summary

The study aimed to identify the clinical value of Magnetic Resonance Imaging examination (MRI)combined with serum squamous cells carcinoma antigen (SCC-Ag) in women with high-grade squamous intraepithelial lesion (cervical intraepithelial neoplasia grades 2-3 (CIN 2-3)).

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: MRI,SCC-Ag

Detailed Description

186 female patients with the HSIL(CIN2-3) were included in this study and followed up from the time of admission. All patients underwent colposcopy examination, MRI, SCC-Ag, loop electrosurgical excision procedure (LEEP), extrafascial hysterectomy, or radical hysterectomy. Pathological findings of the patient's tissues were used as the final diagnostic criteria. On the one hand, we compared the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of MRI+SCC-Ag, LEEP of the menopausal group, and non-menopausal group. On the other hand, evaluating the accuracy of MRI combined with SCC-Ag examination in diagnosing HSIL(CIN2-3) by receiver-operating characteristic curve (ROC).

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
186 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Clinical Value of the MRI Combined With SCC-Ag for the Diagnosis of High-grade Cervical Squamous Neoplasia (Cervical Intra-epithelial Neoplasia Grades 2 and 3 (CIN 2/3))
Actual Study Start Date :
Mar 1, 2021
Anticipated Primary Completion Date :
Aug 1, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
postmenopausal group

Diagnostic Test: MRI,SCC-Ag
Magnetic Resonance Imaging examination,serum squamous cells carcinoma antigen

non-menopausal group

Diagnostic Test: MRI,SCC-Ag
Magnetic Resonance Imaging examination,serum squamous cells carcinoma antigen

Outcome Measures

Primary Outcome Measures

  1. The number of cases whose combined diagnosis of MRI and SCC Ag In postmenopausal women [20 days]

    In postmenopausal women, the number of cases whose combined diagnosis of MRI and SCC Ag consistent with the final pathological results

  2. the number of cases whose combined diagnosis of MRI and SCC Ag for the non-menopausal group. [20 days]

    In non-menopausal women, the number of cases whose combined diagnosis of MRI and SCC Ag consistent with the final pathological results

Eligibility Criteria

Criteria

Ages Eligible for Study:
26 Years to 82 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • No previous history of cervical lesions

  • TCT and HPV test results suspected cervical lesions

  • Further colposcopy showed HSIL or CIN 2-3

  • All selected patients underwent MRI, serological tests for SCC-Ag levels, LEEP, or radical hysterectomy

Exclusion Criteria:
  • Patients with receiving cold knife conization

  • Patients with skin squamous cell carcinoma or previous history of cancer

  • Pregnant women

  • Patients with serious heart, liver, kidney, blood system and autoimmune diseases

Contacts and Locations

Locations

Site City State Country Postal Code
1 The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU Wenzhou Zhejiang China 325000

Sponsors and Collaborators

  • Second Affiliated Hospital of Wenzhou Medical University

Investigators

  • Principal Investigator: Zhao, The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Second Affiliated Hospital of Wenzhou Medical University
ClinicalTrials.gov Identifier:
NCT05487209
Other Study ID Numbers:
  • SAHoWMU-CR2022-07-204
First Posted:
Aug 4, 2022
Last Update Posted:
Aug 4, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Aug 4, 2022